Hannah Bower

List of Publications by Year
in descending order

30 papers	1,174 citations	759055 12 h-index	477173 29 g-index
30 all docs	30 docs citations	30 times ranked	1844 citing authors

#	Article	IF	Citations
1	Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. Journal of Clinical Oncology, 2016, 34, 2851-2857.	0.8	625
2	Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study. Annals of the Rheumatic Diseases, 2021, 80, 1086-1093.	0.5	79
3	Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Annals of the Rheumatic Diseases, 2021, 80, 169-175.	0.5	66
4	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia, 2018, 32, 2203-2210.	3.3	64
5	Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life. Blood Cancer Journal, 2016, 6, e390-e390.	2.8	55
6	Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. British Journal of Cancer, 2017, 117, 1419-1426.	2.9	41
7	Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice. Rheumatology, 2022, 61, 1810-1818.	0.9	31
8	Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. CKJ: Clinical Kidney Journal, 2020, 13, 821-827.	1.4	29
9	Capturing simple and complex time-dependent effects using flexible parametric survival models: A simulation study. Communications in Statistics Part B: Simulation and Computation, 2021, 50, 3777-3793.	0.6	19
10	Strcs: A Command for Fitting Flexible Parametric Survival Models on the Log-hazard Scale. The Stata Journal, 2016, 16, 989-1012.	0.9	16
11	The ORACLE Children Study: educational outcomes at 11â€…years of age following antenatal prescription of erythromycin or co-amoxiclav. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2017, 102, F131-F135.	1.4	16
12	Frailty trajectories in three longitudinal studies of aging: Is the level or the rate of change more predictive of mortality?. Age and Ageing, 2021, 50, 2174-2182.	0.7	16
13	Adjusting Expected Mortality Rates Using Information From a Control Population: An Example Using Socioeconomic Status. American Journal of Epidemiology, 2018, 187, 828-836.	1.6	13
14	Asthma and all-cause mortality in children and young adults: a population-based study. Thorax, 2020, 75, 1040-1046.	2.7	13
15	Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision. RMD Open, 2021, 7, e001987.	1.8	13
16	Loss in working years after a breast cancer diagnosis. British Journal of Cancer, 2018, 118, 738-743.	2.9	11
17	Causes of sick leave, disability pension, and death following a breast cancer diagnosis in women of working age. Breast, 2019, 45, 48-55.	0.9	11
18	Potential gain in life years for Swedish women with breast cancer if stage and survival differences between education groups could be eliminated â€" Three what-if scenarios. Breast, 2019, 45, 75-81.	0.9	10

#	Article	IF	Citations
19	Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. Breast Cancer Research and Treatment, 2020, 182, 699-707.	1.1	8
20	Validation and characterization of venous thromboembolism diagnoses in the Swedish National Patient Register among patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2023, 52, 111-117.	0.6	8
21	OP0034â€¦DOES THE RISK OF VENOUS THROMBOEMBOLISM VARY WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS?. Annals of the Rheumatic Diseases, 2020, 79, 23.2-24.	0.5	7
22	Comparison of treatment retention of originator <i>vs</i> biosimilar products in clinical rheumatology practice in Sweden. Rheumatology, 2022, 61, 3596-3605.	0.9	7
23	Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?. Annals of the Rheumatic Diseases, 2022, 81, 433-439.	0.5	6
24	Assessing the impact of including variation in general population mortality on standard errors of relative survival and loss in life expectancy. BMC Medical Research Methodology, 2022, 22, 130.	1.4	3
25	Temporal Trends in Chronic Myeloid Leukemia Outcome Using the Loss in Expectation of Life: A Swedish Population-Based Study. Blood, 2015, 126, 2779-2779.	0.6	2
26	Potential bias introduced by not including multiple time-scales in survival analysis: a simulation study. Communications in Statistics Part B: Simulation and Computation, 2024, 53, 993-1006.	0.6	2
27	Reply to D. Pulte et al. Journal of Clinical Oncology, 2017, 35, 696-697.	0.8	1
28	POS0601â€¦DIFFERENCES IN DRUG SURVIVAL BETWEEN ORIGINATOR AND BIOSIMILAR PRODUCTS AMONG FIRST USERS OF EACH MOLECULE. Annals of the Rheumatic Diseases, 2021, 80, 535.2-535.	0.5	1
29	POS1169â€¦IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION. Annals of the Rheumatic Diseases, 2021, 80, 864-865.	0.5	1
30	Risk of Bleeding in 9,429 Patients with Philadelphia-Negative Myeloproliferative Neoplasms: a Population-Based Study from Sweden. Blood, 2016, 128, 946-946.	0.6	0